Assessing the clinical development & regulatory pathway for a Phase 3 gene therapy product

Challenge Our client, a PE-backed specialty pharma company growing rapidly through M&A, was assessing a number of late-stage development projects to license/acquire. The company was considering a...
Learn More

Clinical due diligence on a company targeting CNS indications

Challenge A major VC fund asked Alacrita to conduct a clinical due diligence on a potential investment in a company targeting CNS indications. The target company was led by an executive with whom the...
Learn More

Valuation of Rx and OTC products for an investor

Challenge: An investor and asset manager was considering an investment in a European biotech company with one development product for hemophilia and another approved OTC product in an unrelated...
Learn More

Providing due diligence in inflammation and fibrosis area

Challenge: An innovation fund interested in a research institute developing proprietary mAbs against a novel liver disease target, asked Alacrita to conduct due diligence on the development of this...
Learn More

Provision of support for creating an investor prospectus

Challenge: A biotech company focusing in fibrosis and autoimmunity was planning a reverse takeover transaction with a listed entity and required support in formulating its proxy statement (investor...
Learn More

Due diligence on a computational chemistry software for a private equity firm

Challenge: A generalist private equity firm was considering an investment in a computational chemistry company, and required an evaluation of the company’s software suite as part of its due diligence...
Learn More

Technical and commercial due diligence of antibody against metastatic cancers

Challenge: A VC firm was exploring investment in a spin-out company with an antibody targeted at metastatic cancer indications. Before committing to the financing round, the investor required...
Learn More

Pre-DD on re-purposed ophthalmology product

Challenge: A private investment firm was interested in a European drug re-purposing company and asked Alacrita to perform top-level due diligence to help the firm decide whether it wanted to proceed...
Learn More

Due diligence on reinvestment in VC-backed biotech

Challenge: A family office invested in a European, VC-backed company sought Alacrita's expert view of re-investing in the company, following a Phase III trial failure in the immunology space. The...
Learn More

Due diligence on a new biosensor technology

Challenge A company considering an investment in a new early-stage biosensor technology for the measurement of blood pressure needed due diligence support. The product had a number of potential...
Learn More

Providing technical due diligence on a Rubidium-82 radionuclide generator

Challenge Our client was looking to build a capability in radionucleotide imaging and was seeking merger and acquisition opportunities in Europe and the US. One target company was developing a new...
Learn More
1